Business
Longeveron Rights Offering Subscription Period Begins
MIAMI, Aug. 22, 2023 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN NASDAQ: LGVNR) (“Longeveron” or “Company”), a clinical stage biotechnology company
About this update from Longeveron Inc.
[{"type":"text","content":"MIAMI, Aug. 22, 2023 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN NASDAQ: LGVNR) (“Longeveron” or “Company”), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (HLHS), Alzheimer’s disease and Aging-related Frailty, announced today that the subscription period for its previously announced rights offering has begun. The subscription price is $3.00 per share. The subscription period for the rights offering ends at 5:00 p.m. Eastern Time on Thursday, September 21, 2023, unless extended at the Company’s sole discretion. Longeveron reserves the right to modify, extend, postpone or cancel the rights offering at any time prior to the termination of the subscription period or any extension thereof. See our Securities and Exchange Commission filings here for more details about the rights offering as well as information on the Company. EDGAR Search Results (sec.gov). Longeveron has engaged R.F. Lafferty & Co., Inc. to act as dealer-manager for the rights offering. Broker-dealers can contact R.F. Lafferty & Co., Inc. by email at [email protected] or by telephone at (212) 293-9090 to learn more about participating in the rights offering. If you have any questions or need further information about the rights offering, or to request a copy of the prospectus, please call Okapi Partners, Longeveron’s information agent for the rights offering, at (212) 297-0720 (bankers and brokers) or (844) 201-1170 (all others) or email at [email protected]. This press release does not constitute an offer to sell or the solicitation of an offer to buy securities, nor will there be any sale of any securities referred to in this press release in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction. A registration statement relating to the rights was filed with the Securities and Exchange Commission and was declared effective on August 14, 2023. The rights offering is being made only by means of a prospectus filed by the Company with the Securities and Exchange Commission on August 14, 2023. Copies of the prospectus, which contains further details regarding the rights offering, and related rights offering m...